Design Therapeutics
DSGN
96 hedge funds and large institutions have $223M invested in Design Therapeutics in 2023 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 23 increasing their positions, 27 reducing their positions, and 19 closing their positions.
286% more call options, than puts
Call options by funds: $1.09M | Put options by funds: $283K
68% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 19
16% more funds holding
Funds holding: 83 → 96 (+13)
3.04% less ownership
Funds ownership: 72.2% → 69.17% (-3%)
15% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 27
46% less capital invested
Capital invested by funds: $413M → $223M (-$189M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$9.18M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.71M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.09M |
| 4 |
Millennium Management
New York
|
+$2.04M |
| 5 |
Jane Street
New York
|
+$1.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$17.4M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$9.08M |
| 3 |
Rafferty Asset Management
New York
|
-$2.5M |
| 4 |
BlackRock
New York
|
-$2.41M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.08M |
DSGN Hedge Fund Activity: Q1 2023 in Review
96 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q1 2023, worth a combined $223M — down 46% from $413M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new DSGN positions and 19 closed out — a net gain of 13 holders — while 23 added to existing stakes and 27 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $9.18M. The largest seller was State Street, cutting an estimated $17.4M.
- 96 institutional investors held Design Therapeutics (DSGN) as of Q1 2023, up from 83 in Q4 2022.
- Funds reported $223M of Design Therapeutics stock for Q1 2023, down 46% quarter-over-quarter.
- 32 funds opened new Design Therapeutics positions in Q1 2023 and 19 closed out, a net change of +13 holders.
- The largest Design Therapeutics buyer in Q1 2023 was Avoro Capital Advisors, an estimated $9.18M added.
- The largest Design Therapeutics seller in Q1 2023 was State Street, an estimated $17.4M sold.
Based on aggregated 13F filings for Q1 2023.